MARKET

BIOC

BIOC

Biocept Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.450
+0.050
+3.57%
After Hours: 1.580 +0.13 +8.97% 19:27 05/27 EDT
OPEN
1.400
PREV CLOSE
1.400
HIGH
1.460
LOW
1.380
VOLUME
68.05K
TURNOVER
0
52 WEEK HIGH
4.970
52 WEEK LOW
1.330
MARKET CAP
24.54M
P/E (TTM)
-8.9121
1D
5D
1M
3M
1Y
5Y
Biocept's Return On Capital Employed Overview
According to Benzinga Pro data, during Q1, Biocept (NASDAQ:BIOC) posted sales of $19.95 million. Earnings were up 6.84%, but Biocept still reported an overall loss of $2.77 million.
Benzinga · 4d ago
Biocept GAAP EPS of -$0.16 beats by $0.08, revenue of $19.95M beats by $8.46M
Biocept press release (NASDAQ:BIOC): Q1 GAAP EPS of -$0.16 beats by $0.08. Revenue of $19.95M (+12.3% Y/Y) beats by $8.46M. Biocept reported cash and cash equivalents as of March 31,
Seekingalpha · 5d ago
Biocept Q1 EPS $(0.16) Down From $0.19 YoY, Sales $19.90M Up From $17.76M YoY
Biocept (NASDAQ:BIOC) reported quarterly losses of $(0.16) per share. This is a 184.21 percent decrease over earnings of $0.19 per share from the same period last year. The company reported $19.90 million in sales this
Benzinga · 5d ago
Biocept Swings to Q1 Loss, Revenue Rises
MT Newswires · 5d ago
-- Earnings Flash (BIOC) BIOCEPT Posts Q1 Revenue $19.9M
MT Newswires · 5d ago
BRIEF-Biocept Announces Delay In Filing Of Its Quarterly Report On Form 10-Q
reuters.com · 05/16 20:37
Biocept reports delay in filing of Q1 report on Form 10-Q
Biocept (NASDAQ:BIOC) has reported a delay in the filing of its Q122 quarterly report on Form 10-Q. The delay is related to the ongoing accounting review of Biocept’s financial statements
Seekingalpha · 05/16 20:27
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 08, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock t...
Business Wire · 04/08 20:05
More
No Data
Learn about the latest financial forecast of BIOC. Analyze the recent business situations of Biocept Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BIOC stock price target is 9.50 with a high estimate of 12.00 and a low estimate of 7.00.
High12.00
Average9.50
Low7.00
Current 1.450
EPS
Actual
Estimate
-0.10-0.020.070.15
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 2.27M
% Owned: 13.41%
Shares Outstanding: 16.92M
TypeInstitutionsShares
Increased
9
389.63K
New
11
299.28K
Decreased
5
122.55K
Sold Out
7
324.29K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.86%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Chairman/President/Chief Executive Officer/Director
Samuel Riccitelli
Non-Executive Chairman/Independent Director
Margaret Faye Wilson
Chief Financial Officer/Director
Antonino Morales
Chief Operating Officer
Philippe Marchand
Senior Vice President/Chief Compliance Officer/General Counsel
Darrell Taylor
Senior Vice President
Michael Dugan
Senior Vice President
Michael Terry
Chief Compliance Officer/General Counsel
Michael Brown
Vice President/Director of Sales
Antonio Paternostro
Other
Gary Marchetti
Other
Tom Nauman
Other
Tim Schofield
Director
David Hale
Director
Linda Rubinstein
Independent Director
Marsha Chandler
Independent Director
Bruce Gerhardt
Independent Director
Ivor Royston
No Data
No Data
About BIOC
Biocept, Inc. is an early stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor nucleic acid, including circulating tumor deoxyribonucleic acid (ctDNA) and circulating tumor ribonucleic acid (ctRNA), assays using a standard blood sample or liquid biopsy. Its blood and cerebrospinal fluid (CSF) assays are intended to provide information to aid healthcare providers by identifying tumor cells associated with progression or metastasis and identifying specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy. The Company's Target-Selector CTC and molecular platforms provide both biomarker detection as well as monitoring capabilities and require only a patient blood sample or CSF sample to inform treatment decisions. It also offers sensitive polymerase chain reaction (PCR) based assay through Aegea Biotechnologies, Inc. (Aegea) for detecting the COVID-19 virus.

Webull offers kinds of Biocept Inc stock information, including NASDAQ:BIOC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIOC stock methods without spending real money on the virtual paper trading platform.